Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives

Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiefenbacher, Andreas, Pirker, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006273/
https://www.ncbi.nlm.nih.gov/pubmed/29983826
http://dx.doi.org/10.1007/s12254-018-0408-y
_version_ 1783332806876725248
author Tiefenbacher, Andreas
Pirker, Robert
author_facet Tiefenbacher, Andreas
Pirker, Robert
author_sort Tiefenbacher, Andreas
collection PubMed
description Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemotherapy, optimal sequencing of treatments, treatment guidance by means of predictive biomarkers, and value-based judgements of treatments.
format Online
Article
Text
id pubmed-6006273
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-60062732018-07-04 Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives Tiefenbacher, Andreas Pirker, Robert Memo Short Review Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemotherapy, optimal sequencing of treatments, treatment guidance by means of predictive biomarkers, and value-based judgements of treatments. Springer Vienna 2018-05-18 2018 /pmc/articles/PMC6006273/ /pubmed/29983826 http://dx.doi.org/10.1007/s12254-018-0408-y Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Tiefenbacher, Andreas
Pirker, Robert
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title_full Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title_fullStr Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title_full_unstemmed Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title_short Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
title_sort systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006273/
https://www.ncbi.nlm.nih.gov/pubmed/29983826
http://dx.doi.org/10.1007/s12254-018-0408-y
work_keys_str_mv AT tiefenbacherandreas systemictreatmentofadvancednonsmallcelllungcancercontroversiesandperspectives
AT pirkerrobert systemictreatmentofadvancednonsmallcelllungcancercontroversiesandperspectives

Ejemplares similares